Advanced search
Publication Cover
Current Medical Research and Opinion Volume 33, 2017 - Issue 10
Submit an article Journal homepage
708
Views
10
CrossRef citations to date
0
Altmetric
Diabetes

A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy

Yehuda HandelsmanMetabolic Institute of America, Tarzana, CA, USA;
,
Brett LauringMerck & Co., Inc., Kenilworth, NJ, USA
,
Ira GantzMerck & Co., Inc., Kenilworth, NJ, USACorrespondence[email protected]
,
Carol IredaleMerck & Co., Inc., Kenilworth, NJ, USA
,
Edward A. O’NeillMerck & Co., Inc., Kenilworth, NJ, USA
,
Ziwen WeiMerck & Co., Inc., Kenilworth, NJ, USA
,
Shailaja SuryawanshiMerck & Co., Inc., Kenilworth, NJ, USA
,
Keith D. KaufmanMerck & Co., Inc., Kenilworth, NJ, USA
,
Samuel S. EngelMerck & Co., Inc., Kenilworth, NJ, USA
&
Eseng LaiMerck & Co., Inc., Kenilworth, NJ, USA
 show all
Pages 1861-1868 | Received 14 Feb 2017, Accepted 24 May 2017, Published online: 28 Jun 2017

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Mitsuyoshi Takahara, Toshihiko Shiraiwa, Naoto Katakami, Taka-aki Matsuoka & Iichiro Shimomura. (2017) Once-weekly oral antidiabetic agent and treatment satisfaction. Current Medical Research and Opinion 33:11, pages 2093-2094.
Read now

Articles from other publishers (9)

A.B.M. Kamrul-Hasan, Muhammad Shah Alam, Samir Kumar Talukder, Deep Dutta & Shahjada Selim. (2024) Efficacy and Safety of Omarigliptin, a Novel Once-Weekly Dipeptidyl Peptidase-4 Inhibitor, in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Endocrinology and Metabolism 39:1, pages 109-126.
Crossref
A.B.M. Kamrul-Hasan, Muhammad Shah Alam, Samir Kumar Talukder, Deep Dutta & Shahjada Selim. (2024) Efficacy and Safety of Omarigliptin, a Novel Once-Weekly Dipeptidyl Peptidase-4 Inhibitor, in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Endocrinology and Metabolism 39:1, pages 109-126.
Crossref
Y.-H. Chen, Y.-T. Shih, C.-S. Chien & C.-S. Tsai. (2022) Predicting adverse drug effects: A heterogeneous graph convolution network with a multi-layer perceptron approach. PLOS ONE 17:12, pages e0266435.
Crossref
Liyun He, Jialu Wang, Fan Ping, Na Yang, Jingyue Huang, Wei Li, Lingling Xu, Huabing Zhang & Yuxiu Li. (2022) Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials. BMJ, pages e068882.
Crossref
Kasper S Madsen, Pernille Kähler, Lise Katrine Aronsen Kähler, Sten Madsbad, Filip Gnesin, Maria-Inti Metzendorf, Bernd Richter & Bianca Hemmingsen. (2019) Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus. Cochrane Database of Systematic Reviews.
Crossref
Daniela Farah, Graziella Malzoni Leme, Freddy Goldberg Eliaschewitz & Marcelo Cunio Machado Fonseca. (2019) A safety and tolerability profile comparison between dipeptidyl peptidase-4 inhibitors and sulfonylureas in diabetic patients: A systematic review and meta-analysis. Diabetes Research and Clinical Practice 149, pages 47-63.
Crossref
Xianying Wang, Xuejing Li, Suhui Qie, Yingying Zheng, Yang Liu & Guoqiang Liu. (2018) The efficacy and safety of once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus. Medicine 97:34, pages e11946.
Crossref
Rania G. Abdel-latif, Gehan H. Heeba, Ashraf Taye & Mohamed M. A. Khalifa. (2018) Lixisenatide, a novel GLP-1 analog, protects against cerebral ischemia/reperfusion injury in diabetic rats. Naunyn-Schmiedeberg's Archives of Pharmacology 391:7, pages 705-717.
Crossref
Ira Gantz, Taro Okamoto, Yuka Ito, Asako Sato, Kotoba Okuyama, Edward A. O’Neill, Samuel S. Engel & Eseng Lai. (2017) A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control. Diabetes Therapy 8:4, pages 793-810.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.